Wilson Sonsini Goodrich & Rosati advised Nvelop Therapeutics on intellectual property matters related to the transaction. Chroma Medicine and Nvelop Therapeutics announced their merger and subsequent...
Nvelop Therapeutics’ Merger with Chroma
Stoke Therapeutics’ $125 Million Upsized Common Stock Offering
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
Arcellx’s Expansion of Partnership with Kite
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
CARGO Therapeutics’ $281.3 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
Third Rock Ventures’ Investment in CARGO Therapeutics
Orrick advised Third Rock Ventures on the deal while Wilson Sonsini represented CARGO Therapeutics. Third Rock Ventures announced its investment in the $200 million Series A financing...